Biocon Ltd Reports 20% YoY Growth in Q2 FY26 Operating Revenue, Driven by Strong Biosimilars Performance

Biocon Ltd has announced its Q2 FY26 earnings, reporting a 20% year-on-year growth in operating revenue, led by a 25% year-on-year growth in biosimilars, 24% growth in generics, and a 2% growth in CRDMO business. The company's core EBITDA stood at INR 1,218 crores, up 23% year-on-year, with a margin of 28%. R&D investment was INR 251 crores or 7% of revenues, excluding Syngene. The company also announced the launch of four biosimilar products and a partnership with the government of California through Civica Inc. for the supply of affordable insulin glargine under the CalRx initiative.